Does the media favor CHRS or CGEM?

In the previous week, Coherus Oncology had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 4 mentions for Coherus Oncology and 3 mentions for Cullinan Therapeutics. Coherus Oncology's average media sentiment score of 0.97 beat Cullinan Therapeutics' score of 0.60 indicating that Coherus Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CHRS or ABUS?

In the previous week, Coherus Oncology had 2 more articles in the media than Arbutus Biopharma. MarketBeat recorded 4 mentions for Coherus Oncology and 2 mentions for Arbutus Biopharma. Coherus Oncology's average media sentiment score of 0.97 beat Arbutus Biopharma's score of 0.93 indicating that Coherus Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arbutus Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Coherus Oncology (CHRS) Competitors

$1.50 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$1.50 0.00 (0.00%)

As of 06/26/2026 05:21 PM Eastern

Compare

CHRS vs. OLMA, TBPH, ORIC, CGEM, and ABUS

Should you buy Coherus Oncology stock or one of its competitors? MarketBeat compares Coherus Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Coherus Oncology include Olema Pharmaceuticals (OLMA), Theravance Biopharma (TBPH), Oric Pharmaceuticals (ORIC), Cullinan Therapeutics (CGEM), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry.

How does Coherus Oncology compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Olema Pharmaceuticals currently has a consensus price target of $44.10, suggesting a potential upside of 287.18%. Coherus Oncology has a consensus price target of $8.67, suggesting a potential upside of 477.78%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Coherus Oncology is more favorable than Olema Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Coherus Oncology had 3 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 4 mentions for Coherus Oncology and 1 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.89 beat Coherus Oncology's score of 0.97 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Olema Pharmaceuticals	Very Positive
Coherus Oncology	Positive

Coherus Oncology has a net margin of 397.30% compared to Olema Pharmaceuticals' net margin of 0.00%. Olema Pharmaceuticals' return on equity of -46.00% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Coherus Oncology	397.30%	-198.90%	-46.65%

Olema Pharmaceuticals has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Coherus Oncology has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Coherus Oncology	$42.17M	5.49	$168.02M	$1.67	0.90

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by company insiders. Comparatively, 8.1% of Coherus Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Coherus Oncology beats Olema Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Coherus Oncology compare to Theravance Biopharma?

Coherus Oncology (NASDAQ:CHRS) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

In the previous week, Coherus Oncology had 3 more articles in the media than Theravance Biopharma. MarketBeat recorded 4 mentions for Coherus Oncology and 1 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.87 beat Coherus Oncology's score of 0.97 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Coherus Oncology	Positive
Theravance Biopharma	Very Positive

Coherus Oncology has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market.

Coherus Oncology has a net margin of 397.30% compared to Theravance Biopharma's net margin of 104.34%. Theravance Biopharma's return on equity of 18.84% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
Theravance Biopharma	104.34%	18.84%	10.94%

Coherus Oncology has higher earnings, but lower revenue than Theravance Biopharma. Coherus Oncology is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.49	$168.02M	$1.67	0.90
Theravance Biopharma	$107.46M	8.46	$105.89M	$2.20	8.01

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Coherus Oncology presently has a consensus target price of $8.67, suggesting a potential upside of 477.78%. Theravance Biopharma has a consensus target price of $21.40, suggesting a potential upside of 21.38%. Given Coherus Oncology's stronger consensus rating and higher probable upside, equities research analysts clearly believe Coherus Oncology is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Theravance Biopharma	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Coherus Oncology and Theravance Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Coherus Oncology compare to Oric Pharmaceuticals?

Coherus Oncology (NASDAQ:CHRS) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Coherus Oncology had 3 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 4 mentions for Coherus Oncology and 1 mentions for Oric Pharmaceuticals. Coherus Oncology's average media sentiment score of 0.97 beat Oric Pharmaceuticals' score of 0.94 indicating that Coherus Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Coherus Oncology	Positive
Oric Pharmaceuticals	Positive

Coherus Oncology has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.49	$168.02M	$1.67	0.90
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

Coherus Oncology has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Coherus Oncology has a net margin of 397.30% compared to Oric Pharmaceuticals' net margin of 0.00%. Oric Pharmaceuticals' return on equity of -35.33% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

Coherus Oncology currently has a consensus price target of $8.67, suggesting a potential upside of 477.78%. Oric Pharmaceuticals has a consensus price target of $18.92, suggesting a potential upside of 98.50%. Given Coherus Oncology's higher possible upside, research analysts plainly believe Coherus Oncology is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Summary

Coherus Oncology beats Oric Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Coherus Oncology compare to Cullinan Therapeutics?

Coherus Oncology (NASDAQ:CHRS) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Coherus Oncology has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.49	$168.02M	$1.67	0.90
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Coherus Oncology presently has a consensus target price of $8.67, indicating a potential upside of 477.78%. Cullinan Therapeutics has a consensus target price of $32.00, indicating a potential upside of 73.91%. Given Coherus Oncology's stronger consensus rating and higher probable upside, equities analysts plainly believe Coherus Oncology is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Coherus Oncology had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 4 mentions for Coherus Oncology and 3 mentions for Cullinan Therapeutics. Coherus Oncology's average media sentiment score of 0.97 beat Cullinan Therapeutics' score of 0.60 indicating that Coherus Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coherus Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Coherus Oncology has a net margin of 397.30% compared to Cullinan Therapeutics' net margin of 0.00%. Cullinan Therapeutics' return on equity of -51.45% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Coherus Oncology has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market.

Summary

Coherus Oncology beats Cullinan Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Coherus Oncology compare to Arbutus Biopharma?

Coherus Oncology (NASDAQ:CHRS) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Coherus Oncology had 2 more articles in the media than Arbutus Biopharma. MarketBeat recorded 4 mentions for Coherus Oncology and 2 mentions for Arbutus Biopharma. Coherus Oncology's average media sentiment score of 0.97 beat Arbutus Biopharma's score of 0.93 indicating that Coherus Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coherus Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arbutus Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Coherus Oncology has higher revenue and earnings than Arbutus Biopharma. Coherus Oncology is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.49	$168.02M	$1.67	0.90
Arbutus Biopharma	$14.08M	64.05	-$33.50M	$0.83	5.50

Coherus Oncology has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

Coherus Oncology presently has a consensus target price of $8.67, suggesting a potential upside of 477.78%. Arbutus Biopharma has a consensus target price of $5.00, suggesting a potential upside of 9.53%. Given Coherus Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe Coherus Oncology is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Coherus Oncology has a net margin of 397.30% compared to Arbutus Biopharma's net margin of 83.95%. Arbutus Biopharma's return on equity of 129.32% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
Arbutus Biopharma	83.95%	129.32%	112.24%

Summary

Coherus Oncology beats Arbutus Biopharma on 11 of the 16 factors compared between the two stocks.

Get Coherus Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CHRS vs. The Competition

Export

Metric	Coherus Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$231.38M	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	0.90	21.75	25.89	24.17
Price / Sales	5.49	334.18	546.41	101.77
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	3.00	8.31	10.79	6.38
Net Income	$168.02M	$23.92M	$3.58B	$337.00M
7 Day Performance	1.35%	1.93%	1.97%	-0.20%
1 Month Performance	-5.66%	-0.41%	-0.24%	-1.40%
1 Year Performance	101.86%	65.22%	34.40%	27.76%

Coherus Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CHRS Coherus Oncology	3.7333 of 5 stars	$1.50 flat	$8.67 +477.8%	+101.9%	$231.38M	$42.17M	0.90	330	High Trading Volume
OLMA Olema Pharmaceuticals	2.8096 of 5 stars	$9.88 +0.1%	$44.10 +346.4%	+146.5%	$862.12M	N/A	N/A	70	Negative News
TBPH Theravance Biopharma	3.4698 of 5 stars	$16.32 -1.9%	$21.83 +33.8%	+57.1%	$857.84M	$107.46M	7.42	110	Positive News
ORIC Oric Pharmaceuticals	2.3386 of 5 stars	$8.40 +1.6%	$18.92 +125.2%	-7.6%	$856.09M	N/A	N/A	80	Gap Up
CGEM Cullinan Therapeutics	2.6759 of 5 stars	$13.61 -0.7%	$32.00 +135.1%	+137.1%	$841.97M	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CHRS) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coherus Oncology (CHRS) Competitors

CHRS vs. OLMA, TBPH, ORIC, CGEM, and ABUS

How does Coherus Oncology compare to Olema Pharmaceuticals?

Summary

How does Coherus Oncology compare to Theravance Biopharma?

Summary

How does Coherus Oncology compare to Oric Pharmaceuticals?

Summary

How does Coherus Oncology compare to Cullinan Therapeutics?

Summary

How does Coherus Oncology compare to Arbutus Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coherus Oncology (CHRS) Competitors

CHRS vs. OLMA, TBPH, ORIC, CGEM, and ABUS

How does Coherus Oncology compare to Olema Pharmaceuticals?

Do analysts prefer OLMA or CHRS?

Does the media refer more to OLMA or CHRS?

Is OLMA or CHRS more profitable?

Which has more risk & volatility, OLMA or CHRS?

Which has higher earnings and valuation, OLMA or CHRS?

Do insiders & institutionals hold more shares of OLMA or CHRS?

Summary

How does Coherus Oncology compare to Theravance Biopharma?

Does the media refer more to CHRS or TBPH?

Which has more risk and volatility, CHRS or TBPH?

Is CHRS or TBPH more profitable?

Which has stronger valuation and earnings, CHRS or TBPH?

Do insiders and institutionals believe in CHRS or TBPH?

Do analysts rate CHRS or TBPH?

Summary

How does Coherus Oncology compare to Oric Pharmaceuticals?

Do insiders & institutionals believe in CHRS or ORIC?

Does the media refer more to CHRS or ORIC?

Which has better earnings & valuation, CHRS or ORIC?

Which has more volatility and risk, CHRS or ORIC?

Is CHRS or ORIC more profitable?

Do analysts rate CHRS or ORIC?

Summary

How does Coherus Oncology compare to Cullinan Therapeutics?

Which has better valuation and earnings, CHRS or CGEM?

Do institutionals & insiders believe in CHRS or CGEM?

Do analysts rate CHRS or CGEM?

Does the media favor CHRS or CGEM?

Is CHRS or CGEM more profitable?

Which has more risk and volatility, CHRS or CGEM?

Summary

How does Coherus Oncology compare to Arbutus Biopharma?

Do insiders & institutionals hold more shares of CHRS or ABUS?

Does the media favor CHRS or ABUS?

Which has stronger earnings and valuation, CHRS or ABUS?

Which has more volatility & risk, CHRS or ABUS?

Do analysts prefer CHRS or ABUS?

Is CHRS or ABUS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools